{"gene":"STAT5B","run_date":"2026-06-10T07:46:42","timeline":{"discoveries":[{"year":1995,"finding":"STAT5B (then called Stat5b) was cloned from mouse mammary tissue and shown to recognize GAS sites (TTCNNNGAA) in vitro and mediate prolactin-induced transcription in COS cells co-transfected with the prolactin receptor, establishing its role as a transcriptional activator downstream of prolactin/JAK2 signaling.","method":"cDNA cloning, in vitro DNA-binding assays, COS cell transfection with PRL receptor and reporter genes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA-binding assays plus functional transcriptional reconstitution in COS cells; foundational cloning paper replicated by many subsequent studies","pmids":["7568026"],"is_preprint":false},{"year":1996,"finding":"STAT5B is activated by IL-2 in peripheral blood lymphocytes and NK-like cells. IL-2-induced STAT5B DNA-binding activity in COS-7 cells requires JAK3, the IL-2Rβ chain, the common γ-chain, and either Tyr-392 or Tyr-510 of IL-2Rβ as docking sites. Tyr-699 of STAT5B is required for dimerization.","method":"COS-7 reconstitution with specific antisera, dominant-negative constructs, site-directed tyrosine mutants of IL-2Rβ and STAT5B","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution system with mutagenesis of multiple tyrosine residues, replicated across multiple cell types","pmids":["8631883"],"is_preprint":false},{"year":1996,"finding":"Upon prolactin-induced tyrosine phosphorylation, STAT5A and STAT5B form homo- and heterodimers and translocate to the nucleus, where both isoforms contribute to the DNA-binding activity detected during lactation. Stat5b homodimers are less abundant than Stat5a homodimers in mammary cells.","method":"Isoform-specific antibodies, EMSA, supershift analysis, immunodepletion, co-immunoprecipitation in mammary tissue/cells","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal biochemical methods (EMSA, IP, supershift) in physiologically relevant mammary tissue; replicated in subsequent studies","pmids":["8961260"],"is_preprint":false},{"year":1997,"finding":"Growth hormone induces tyrosyl phosphorylation of both STAT5A and STAT5B, and JAK2 kinase is required for GH-dependent tyrosyl phosphorylation of STAT5B. The GH receptor's C-terminal cytoplasmic domain and Tyr-333/338 are required for maximal STAT5B activation.","method":"COS cell expression with GHR truncation/mutation constructs, JAK2-deficient cell lines (gamma2A-GHR vs. 2C4-GHR), Western blotting, EMSA","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — JAK2-deficient cell line rescue and GHR mutagenesis establishing mechanistic requirements; multiple orthogonal methods","pmids":["9231797"],"is_preprint":false},{"year":1998,"finding":"STAT5A and STAT5B homodimers have distinct DNA-binding specificities determined by a single amino acid: Gly-433 in STAT5B (vs. Glu at the equivalent position in STAT5A) in the DNA-binding domain determines their differential DNA-binding preference.","method":"Chimeric STAT5 molecules, site-directed mutagenesis, EMSA with different GAS-site oligonucleotides","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with chimeric proteins plus point mutagenesis identifying single residue responsible for specificity difference","pmids":["9852045"],"is_preprint":false},{"year":1998,"finding":"In mammary cells, STAT5A, STAT5B, and the glucocorticoid receptor (GR) are physically associated in vivo independently of lactogenic hormone treatment. Upon lactogenic hormone treatment, Stat5a-Stat5b heterodimers form and translocate to the nucleus. The GR does not bind the Stat5 DNA-binding site directly but is detectable in the Stat5-DNA complex, suggesting GR acts as a cofactor for milk protein gene transcription.","method":"Co-immunoprecipitation, immunodepletion, EMSA, HC11 mammary cell experiments at different developmental stages","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, immunodepletion, EMSA with supershift, multiple physiological contexts","pmids":["9528750"],"is_preprint":false},{"year":1998,"finding":"STAT5B is essential for IL-2- and IL-15-mediated NK cell proliferation and cytolytic activity. Stat5b-/- mice show greatly diminished NK cell numbers and responsiveness, and diminished IL-2Rβ chain expression, establishing STAT5B as a non-redundant regulator of NK cell function via IL-2Rβ expression.","method":"Stat5b-knockout mice, anti-CD3 proliferation assays, NK cytolytic activity assays, flow cytometry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype and molecular correlate (IL-2Rβ expression); replicated across IL-2 and IL-15 systems","pmids":["9841920"],"is_preprint":false},{"year":1998,"finding":"Stat5a and Stat5b have essential and often redundant roles in cytokine responses. Stat5a is specifically required for prolactin-induced mammary gland development, while Stat5b is specifically required for growth hormone-mediated pubertal growth and sex-specific liver gene expression. Deletion of both leads to more severe phenotypes than single knockouts.","method":"Individual and double Stat5a/Stat5b gene-targeted knockout mice; phenotypic analysis of mammary, hepatic, and hematopoietic responses","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mice with defined tissue-specific phenotypes; multiple cytokine systems tested; widely replicated","pmids":["9630227"],"is_preprint":false},{"year":1999,"finding":"STAT5B is required for GH pulse-induced SOCS-2 and SOCS-3 expression in liver but not in mammary gland, demonstrating tissue-specific STAT5B-dependent regulation of negative feedback inhibitors of cytokine signaling.","method":"Comparison of GH-induced SOCS mRNA expression in wild-type vs. STAT5b-deficient mice by Northern/RT-PCR","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO comparison with tissue-specific resolution; single lab but clear genetic epistasis","pmids":["10630411"],"is_preprint":false},{"year":1999,"finding":"STAT5B is required for GH pulse responsiveness in liver. STAT5b-deficient mice fail to respond to pulsatile GH replacement with normal body weight gain, male-specific CYP2D9 expression, or suppression of female-specific CYP2B enzymes, establishing STAT5B as an essential mediator of pulsatile GH-driven sex-specific liver gene expression.","method":"Hypophysectomized wild-type vs. STAT5b-deficient mice with pulsatile GH replacement; liver P450 enzyme measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with pharmacological rescue (GH replacement) and multiple molecular readouts","pmids":["10585399"],"is_preprint":false},{"year":1999,"finding":"Termination of GH pulse-induced STAT5B signaling involves: (1) synthesis of a labile protein factor (blocked by cycloheximide), (2) proteasome-dependent degradation (blocked by MG132), and (3) dephosphorylation by a phosphotyrosine phosphatase (blocked by pervanadate). A serine kinase (H7-sensitive) is required for down-regulation of JAK2 signaling to STAT5B.","method":"Rat liver cell line CWSV-1 with pharmacological inhibitors (cycloheximide, MG132, pervanadate, H7), kinetic Western blotting","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple mechanistic inhibitor experiments in a cell-based system, dissecting sequential pathway steps; single lab but multiple orthogonal inhibitors","pmids":["9892011"],"is_preprint":false},{"year":1999,"finding":"Continuous (female-pattern) GH exposure down-regulates STAT5B activity in liver cells via enhanced dephosphorylation of both STAT5B and GHR-JAK2, with the latter step leading to increased internalization/degradation of the receptor-kinase complex. Pervanadate treatment reverses the down-regulation, confirming phosphotyrosine phosphatase involvement.","method":"CWSV-1 rat liver cell line, continuous vs. pulsatile GH treatment, pervanadate/proteasome inhibitors, EMSA for STAT5B DNA-binding activity","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mechanistic pharmacological dissection in liver cell model, multiple inhibitors, EMSA functional readouts; single lab","pmids":["9973252"],"is_preprint":false},{"year":1999,"finding":"PRL-activated STAT5B selectively translocates to the nucleus upon src kinase activation, but src activation (unlike prolactin) does not activate a beta-casein reporter, suggesting src and JAK2 activate STAT5B via distinct mechanisms resulting in differential nuclear function. The C-terminal sequences of STAT5B mediate its selective nuclear translocation by src.","method":"Indirect immunofluorescence microscopy, dominant-negative JAK2 overexpression, co-transfection assays with beta-casein-luciferase reporter","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular localization with functional consequence (reporter assay), dominant-negative approach; single lab, limited mechanistic follow-up of C-terminal domain requirement","pmids":["10428824"],"is_preprint":false},{"year":1999,"finding":"PRL-activated STAT5B inhibits NF-κB-mediated transcription by competing for limiting coactivators (p300/CBP) in the nucleus. This inhibitory effect requires the C-terminus of STAT5B and STAT5B nuclear translocation, but is independent of STAT5B-DNA interactions.","method":"Co-transfection assays with NF-κB reporters, dominant-negative STAT5B, p300/CBP co-expression titration experiments","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter constructs and domain-deletion approach identify mechanism; single lab, COS cell system","pmids":["10628751"],"is_preprint":false},{"year":2000,"finding":"PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5A and STAT5B in COS7 cells and in vitro. Overexpression of PTP1B inhibits nuclear translocation of both STAT5 isoforms and PRL-induced beta-casein gene transcription. Substrate-trapping PTP1B mutants co-precipitate tyrosine-phosphorylated STAT5.","method":"In vitro phosphatase assays, co-precipitation with substrate-trapping PTP1B mutants, retrovirus-mediated overexpression in mammary epithelial cells, reporter gene assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro assay plus substrate-trapping, functional consequences in physiologically relevant cell type; multiple orthogonal methods","pmids":["10993888"],"is_preprint":false},{"year":2000,"finding":"In platelets stimulated with thrombopoietin (TPO), CrkL adapter protein is present in DNA-bound STAT5 complexes and binds predominantly to STAT5B, identifying CrkL as a STAT5B-associated protein in TPO signaling.","method":"EMSA, immunoprecipitation, Western blotting in TPO-stimulated human platelets","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-precipitation from physiologically stimulated primary cells; single method for CrkL-STAT5B association; single lab","pmids":["10720694"],"is_preprint":false},{"year":2002,"finding":"STAT5B shuttles constitutively between nucleus and cytoplasm as a monomer (independent of cytokine stimulation), via a CRM1-dependent nuclear export mechanism. Cytokine-dependent nuclear import uses a different mechanism requiring Tyr-699 phosphorylation and dimerization, and the coiled-coil domain. The nuclear export is sensitive to leptomycin B.","method":"Leptomycin B treatment, Tyr-699 mutant STAT5B, deletion mutants, nuclear/cytoplasmic fractionation, immunofluorescence in Ba/F3 cells","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — domain mapping with multiple mutants, pharmacological inhibitor, two distinct import/export mechanisms defined; single lab","pmids":["11971004"],"is_preprint":false},{"year":2002,"finding":"STAT5B mediates EGF-induced DNA synthesis downstream of EGFR overexpression and c-Src co-overexpression. EGF-induced phosphorylation of STAT5B requires Tyr-845 of the EGFR (phosphorylated by c-Src). STAT5B phosphorylation involves Tyr-699 (required for transcriptional activation) and Tyr-725/740/743 in the C-terminus.","method":"Site-specific EGFR tyrosine mutants, dominant-negative STAT5B, kinase-defective c-Src, breast tumor cell lines and C3H10T1/2 fibroblasts, [3H]-thymidine incorporation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple site-directed mutants of both EGFR and STAT5B, dominant-negative approach, functional DNA synthesis readout; single lab","pmids":["12429742"],"is_preprint":false},{"year":2002,"finding":"STAT5b-RARα fusion protein (APL) binds retinoic acid response elements (RAREs) as homodimer and as heterodimer with RXRα, inhibiting wild-type RARα/RXRα transactivation. The coiled-coil domain of STAT5b is required for homodimerization, inhibition of RARα/RXRα activity, and stability of the STAT5b-RARα/SMRT complex. STAT5b-RARα also enhances STAT3-dependent transcription via a distinct mechanism.","method":"RARE reporter assays, SMRT/TRAM-1 co-IP, domain deletion/mutation analysis in transfected cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter assays and co-IP with domain dissection; single lab, fusion protein context","pmids":["11929748"],"is_preprint":false},{"year":2003,"finding":"Ligand-activated PPARα and PPARγ inhibit GH-induced, STAT5B-dependent transcription by up to ~80% without blocking STAT5B tyrosine phosphorylation or DNA binding. The inhibition requires the AF-1 (N-terminal) domain of PPARα and occurs downstream of STAT5B activation, suggesting competition for nuclear cofactors. Conversely, GH-activated STAT5B also inhibits PPAR-regulated transcription, demonstrating bidirectional cross-inhibition.","method":"COS-1 cell co-transfection with PPAR and STAT5B reporters, PPAR domain mutants, constitutively active STAT5B, Western blotting for phosphorylation status","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple PPAR mutants and constitutively active STAT5B define mechanistic step; single lab, cell transfection system","pmids":["12869640"],"is_preprint":false},{"year":2003,"finding":"IFN-γ preferentially activates STAT5B (not STAT5A) in primary human dermal fibroblasts, and this activation is required for IFN-γ-induced upregulation of IGF-I mRNA. In fibroblasts with non-functional STAT5B, only STAT5A is activated and IGF-I induction is severely blunted, demonstrating that STAT5A cannot substitute for STAT5B in IGF-I transcriptional regulation.","method":"Primary human fibroblasts with functional vs. non-functional STAT5B, IFN-γ stimulation, nuclear translocation assays, IGF-I mRNA quantification","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — natural human cell genetic comparison plus nuclear localization tracking; single lab, primary cells","pmids":["14570891"],"is_preprint":false},{"year":2003,"finding":"A NOD mouse mutation (L327M) in the DNA-binding domain of Stat5b results in weaker DNA binding, confirmed by DNA-protein binding assays and correlated with decreased mRNA and protein levels of Stat5b target genes IL-2Rβ and Pim1.","method":"Sequencing, homology modeling, DNA-protein binding assays (EMSA), Western blotting comparing NOD vs. B6 mice","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus binding assays plus in vivo target gene expression; single lab","pmids":["14701862"],"is_preprint":false},{"year":2006,"finding":"HNF4α inhibits GH-activated STAT5B transcriptional activity by blocking GH-stimulated JAK2 tyrosine phosphorylation (upstream mechanism), while STAT5B synergistically enhances HNF4α-driven transcription of ApoCIII. This bidirectional cross-talk is selective (HNF4α does not affect IFN-γ/STAT1 activity).","method":"HepG2 cell co-transfection, dominant-negative PTP1B, pervanadate treatment, JAK2 and STAT5B phosphorylation Western blotting, promoter-reporter assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple promoter-reporter assays and phosphorylation analysis with pharmacological controls defining point of cross-talk; single lab","pmids":["16584384"],"is_preprint":false},{"year":2006,"finding":"In T lymphocytes, glucocorticoids recruit STAT5B to the P4 promoter of bcl-X. STAT5B remains bound while GR is released; subsequent co-recruitment of SMRT and HDAC3 leads to histone H3 deacetylation, RNA Pol II departure, and transcriptional repression. Inhibition of STAT5 activity converts glucocorticoid repression to activation. [Note: paper is marked as retracted.]","method":"ChIP assays in S49 T cells and primary thymocytes, STAT5 inhibitor, STAT5B co-transfection","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 2 / Weak — paper is retracted; ChIP-based mechanistic finding cannot be relied upon","pmids":["16959781"],"is_preprint":false},{"year":2006,"finding":"CrkL adapter protein co-precipitates with Stat5b and is a binding cofactor that enhances Stat5b DNA-binding ability. Recombinant CrkL profection significantly increases Stat5b DNA binding and rescues the binding defect of the NOD mutant Stat5b.","method":"Co-immunoprecipitation, recombinant protein profection, EMSA in NOD and congenic mouse backgrounds","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue with recombinant protein establishes CrkL as STAT5B binding cofactor; single lab","pmids":["16505237"],"is_preprint":false},{"year":2010,"finding":"STAT5B associates constitutively with the C-terminal tail of the δ-opioid receptor (δ-OR). δ-OR stimulation leads to STAT5B tyrosine phosphorylation in a G protein (Gi/Go) and c-Src kinase-dependent manner. STAT5B, c-Src, and selective Gα and Gβγ subunits form a multi-component signaling complex (signalosome) at the δ-OR C-terminus.","method":"Co-immunoprecipitation in HEK293 cells stably expressing δ-OR, pertussis toxin (G protein inhibition), c-Src kinase assays, STAT5B transcriptional reporter assays","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, pharmacological G protein inhibition, and transcriptional assays; single lab","pmids":["20433855"],"is_preprint":false},{"year":2012,"finding":"STAT5B Ser-193 is a novel cytokine-induced (IL-2, IL-7, IL-9, IL-15) phosphorylation site that occurs in the cytoplasm prior to nuclear translocation. Ser-193 phosphorylation is sensitive to mTOR inhibitors (rapamycin) and enhanced by PP2A inhibition. Ser-193 phosphorylation is required for maximal STAT5B transcriptional activity (confirmed by site-directed mutagenesis). Constitutive Ser-193 phosphorylation is found in primary leukemia/lymphoma cells.","method":"Mass spectrometry identification, phospho-specific antibodies, mTOR/PP2A inhibitors, site-directed mutagenesis, HEK293 reconstitution assays, EMSA, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry identification of novel PTM site, site-directed mutagenesis confirming functional requirement, multiple orthogonal assays; single lab","pmids":["22442148"],"is_preprint":false},{"year":2012,"finding":"ΔEGFR (EGFRvIII) activates STAT5B at Y699 in a Src family kinase-dependent manner (distinct from full-length EGF-stimulated EGFR). Phosphorylated STAT5B and ΔEGFR form a nuclear complex that binds DNA and occupies promoters (including Bcl-XL and Aurora A). STAT5B knockdown reduces Bcl-XL levels and sensitizes glioblastoma cells to cisplatin.","method":"Co-immunoprecipitation, ChIP, siRNA knockdown, cisplatin cytotoxicity assays in glioblastoma cell lines and patient samples","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, ChIP, and functional knockdown studies; single lab, multiple orthogonal methods","pmids":["22729867"],"is_preprint":false},{"year":2015,"finding":"Activating mutations of STAT5B (particularly N642H in the SH2 domain) are frequent in γδ-T and NK-cell lymphomas. The N642H mutation markedly increases the binding affinity of phosphotyrosine-Y699 for the SH2 domain (measured by surface plasmon resonance), prolonging phospho-STAT5B persistence and increasing binding to target sites.","method":"Next-generation and Sanger sequencing, surface plasmon resonance, molecular modelling, phospho-STAT5B Western blotting, JAK inhibitor growth assays in transduced cell lines and primary NK cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — biophysical SPR measurement of binding affinity, molecular modelling, and functional cell assays; multiple lymphoma cohorts","pmids":["25586472"],"is_preprint":false},{"year":2017,"finding":"Cryptochromes (CRY1/2) control IGF-1 circadian rhythms by regulating JAK2-dependent phosphorylation of STAT5B at Y699 (JAK2-dependent site). Cry-deficient mice show markedly reduced Y699 STAT5B phosphorylation in liver and skeletal muscle despite normal JAK2 phosphorylation, placing CRY activity downstream of JAK2 in the IGF-1 pathway.","method":"Cry-deficient mouse model, phospho-specific STAT5B and JAK2 Western blotting in liver and skeletal muscle, IGF-1 ELISA, Igf-1 mRNA quantification","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with phospho-specific antibodies establishing pathway position downstream of JAK2; single lab","pmids":["28100634"],"is_preprint":false},{"year":2017,"finding":"Musculin (MSC), expressed in human Th17 cells in a RORγt-dependent manner, upregulates PP2A regulatory subunit PPP2R2B, which dephosphorylates STAT5B Ser-193, reducing STAT5B DNA binding and transcriptional activity on IL-2 target genes in Th17 cells.","method":"siRNA knockdown of MSC and PPP2R2B, PP2A assays, STAT5B Ser-193 phospho-Western blotting, EMSA, reporter assays in primary human Th17 cells","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway from RORγt → MSC → PPP2R2B → PP2A → STAT5B Ser-193 dephosphorylation defined by knockdown and phospho-specific readouts; single lab","pmids":["28612433"],"is_preprint":false},{"year":2018,"finding":"Dominant-negative STAT5B missense mutations cause growth hormone insensitivity by two distinct mechanisms: either failure of nuclear localization or failure to bind canonical STAT5B DNA response elements. Despite being robustly tyrosine-phosphorylated, each mutant retains the ability to dimerize with wild-type STAT5B, disrupting wild-type transcriptional functions.","method":"Patient-derived cell studies, GH stimulation/phosphorylation assays, nuclear localization imaging, EMSA, co-IP for dimerization with wild-type STAT5B","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple patient mutations characterized with functional assays (phosphorylation, localization, DNA binding, dimerization), distinguishing mechanistic pathomechanisms; replicated across several mutations","pmids":["29844444"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of human STAT5B and STAT5B-N642H reveal that the N642H mutation leads to alternative SH2 domain conformations. Biophysical data indicate that STAT5B-N642H can adopt both hyper-activated and hyper-inactivated states with resistance to dephosphorylation. MD simulations show sustained interchain cross-domain interactions in N642H, conferring kinetic stability to the mutant anti-parallel dimer.","method":"X-ray crystallography, molecular dynamics simulations, biophysical dephosphorylation assays, transgenic mouse model, syngeneic transplant models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of wild-type and mutant protein combined with biophysical assays and in vivo mouse models; multiple orthogonal methods","pmids":["31175292"],"is_preprint":false},{"year":2019,"finding":"STAT5B (but not STAT5A) is the major STAT5 isoform driving BCR/ABL+ leukemia. STAT5B-deficient BCR/ABL+ cells have markedly enhanced IFN-α and IFN-γ signaling signatures, and inhibition of IFN responses rescues BCR/ABL+ colony formation of Stat5b-deficient cells, demonstrating that STAT5B enables leukemic transformation by suppressing IFN-α/γ responses.","method":"STAT5A/B-specific knockouts in BCR/ABL cell models, RNA-seq profiling, IFN pathway inhibition rescue experiments, leukemia transplant models","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with RNA-seq and functional rescue by IFN inhibition; multiple experimental approaches and in vivo model","pmids":["30679796"],"is_preprint":false},{"year":2022,"finding":"STAT5B restrains IL-21-induced human B-cell differentiation into plasmablasts by inducing SOCS3 (which attenuates IL-21 signaling) and BCL6 (which represses plasma cell formation and class switching). CRISPR-mediated STAT5B deletion in B-cell lines diminishes IL-21-mediated SOCS3 induction; STAT5B-null patients have expanded immunoglobulin class-switched B cells and follicular T helper cells.","method":"CRISPR-mediated STAT5B deletion in B-cell lines, phospho-flow cytometry, RNA-seq, patient PBMC studies, in vitro B-cell differentiation assays","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR deletion plus human patient validation, RNA-seq, and functional differentiation assays; multiple orthogonal methods","pmids":["35469842"],"is_preprint":false},{"year":2024,"finding":"Tyrosine phosphorylation of both STAT5A and STAT5B (at the C-terminal tyrosine) is essential for maximal IL-2 signaling and CD8+ T-cell proliferation in vivo. Tyrosine-to-phenylalanine knockin mice show reduced CD8+ T cells, impaired IL-2-induced proliferation correlated with reduced Myc, pRB, cyclins, CDKs, and a partial G1→S block, as well as decreased IL-2Rβ and IL-2Rγ expression and reduced pERK and pAKT.","method":"Knockin mice with Tyr-to-Phe mutations in STAT5A and STAT5B, flow cytometry, transcriptomics (RNA-seq), proteomics, cell cycle analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockin mouse model with transcriptomic and proteomic analyses; multiple orthogonal methods establishing in vivo requirement for STAT5B tyrosine phosphorylation","pmids":["39191751"],"is_preprint":false}],"current_model":"STAT5B is a latent cytoplasmic transcription factor that is activated by JAK2-mediated tyrosine phosphorylation (at Y699) downstream of multiple cytokine receptors (GHR, IL-2R, PRL-R, EpoR, and others), whereupon it dimerizes—forming homodimers with a DNA-binding preference determined by Gly-433—and translocates to the nucleus via two mechanisms (constitutive CRM1-dependent monomer shuttling and cytokine-induced dimer import); maximal transcriptional activity additionally requires Ser-193 phosphorylation by an mTOR-sensitive kinase; dephosphorylation by PTP1B terminates signaling; STAT5B regulates distinct target genes from STAT5A (single residue in the DNA-binding domain confers specificity), mediates GH-pulsatile sex-specific liver gene expression, IGF-1 production, NK cell maturation and cytolytic function, Treg homeostasis (via FOXP3 and IL-2Rα), B-cell differentiation restraint (via SOCS3/BCL6), and suppresses IFN-α/γ responses to facilitate leukemogenesis; gain-of-function mutations (especially N642H in the SH2 domain) increase pY-STAT5B persistence by enhancing phosphotyrosine–SH2 affinity and conferring dephosphorylation resistance, as revealed by crystal structures of wild-type and mutant STAT5B."},"narrative":{"mechanistic_narrative":"STAT5B is a latent cytoplasmic transcription factor that converts cytokine and growth-factor receptor engagement into GAS-element–driven gene expression, functioning downstream of prolactin, IL-2, growth hormone, and other receptors [PMID:7568026, PMID:8631883, PMID:9231797]. Receptor-associated JAK kinases phosphorylate STAT5B on Tyr-699, which is required for dimerization and is the obligate step for cytokine-induced nuclear import; in resting cells STAT5B shuttles constitutively as a monomer via a CRM1-dependent export route, whereas activated dimers use a distinct Tyr-699/coiled-coil–dependent import mechanism [PMID:8631883, PMID:11971004]. Maximal transcriptional output further requires a cytoplasmic, mTOR-sensitive Ser-193 phosphorylation that precedes nuclear translocation [PMID:22442148]. STAT5B and the paralog STAT5A diverge functionally: a single DNA-binding-domain residue (Gly-433 in STAT5B versus Glu in STAT5A) sets differential GAS-site preference, and STAT5B is selectively required for growth-hormone–driven, sex-specific liver gene expression while STAT5A governs prolactin-induced mammary development [PMID:9852045, PMID:9630227, PMID:10585399]. Through these activities STAT5B controls NK-cell proliferation and cytolytic function via IL-2Rβ, IFN-γ–induced IGF-1 production, and restraint of IL-21–driven B-cell differentiation through SOCS3 and BCL6 induction [PMID:9841920, PMID:14570891, PMID:35469842]. Signaling is terminated by phosphotyrosine dephosphorylation, with PTP1B acting as a direct STAT5B phosphatase, together with serine-kinase- and proteasome-dependent feedback [PMID:9892011, PMID:10993888]. STAT5B drives leukemic transformation, in part by suppressing IFN-α/γ responses in BCR/ABL+ cells, and recurrent activating mutations—notably N642H in the SH2 domain—prolong phospho-STAT5B persistence by increasing phosphotyrosine–SH2 affinity and conferring dephosphorylation resistance, as defined by surface plasmon resonance and crystal structures of wild-type and mutant protein [PMID:25586472, PMID:31175292, PMID:30679796]. Dominant-negative missense mutations in STAT5B cause growth hormone insensitivity by impairing either nuclear localization or DNA binding while still dimerizing with and poisoning wild-type protein [PMID:29844444].","teleology":[{"year":1995,"claim":"Established STAT5B as a sequence-specific transcriptional activator acting downstream of cytokine receptor signaling, answering whether the cloned factor could directly drive hormone-induced transcription.","evidence":"cDNA cloning, in vitro GAS-site DNA-binding assays, and prolactin-receptor reporter reconstitution in COS cells","pmids":["7568026"],"confidence":"High","gaps":["Did not define the upstream kinase or activation residues","No endogenous target genes identified"]},{"year":1996,"claim":"Defined the receptor architecture and the obligate dimerization residue, showing STAT5B activation requires JAK3/IL-2Rβ docking tyrosines and STAT5B Tyr-699.","evidence":"COS-7 reconstitution with dominant-negative constructs and tyrosine point mutants of IL-2Rβ and STAT5B; EMSA in lymphocytes","pmids":["8631883","8961260"],"confidence":"High","gaps":["Did not address how the two paralogs differ functionally","Mechanism of nuclear import not yet defined"]},{"year":1997,"claim":"Placed STAT5B activation downstream of JAK2 at the growth hormone receptor, establishing the GHR cytoplasmic determinants required for phosphorylation.","evidence":"GHR truncation/mutation constructs and JAK2-deficient cell line rescue with Western blotting and EMSA","pmids":["9231797"],"confidence":"High","gaps":["Did not separate STAT5B from STAT5A physiological roles","In vivo GH consequences untested"]},{"year":1998,"claim":"Resolved paralog specificity, showing a single DNA-binding-domain residue (Gly-433) governs differential GAS-site preference and that STAT5A and STAT5B have non-redundant tissue roles.","evidence":"Chimeric proteins and point mutagenesis with EMSA; individual and double Stat5a/Stat5b knockout mice","pmids":["9852045","9630227","9841920"],"confidence":"High","gaps":["Mechanistic basis for tissue-restricted requirement unresolved","How a single residue rewires target selection in vivo not mapped"]},{"year":1999,"claim":"Defined STAT5B as the essential mediator of pulsatile GH-driven, sex-specific liver gene expression and dissected the multi-step termination of GH signaling.","evidence":"Hypophysectomized STAT5b-deficient mice with pulsatile GH replacement and liver P450 readouts; rat liver cell models with cycloheximide, MG132, pervanadate, and H7 inhibitors","pmids":["10585399","10630411","9892011","9973252"],"confidence":"High","gaps":["Identity of the labile feedback protein not established","Specific serine kinase and phosphatase not molecularly identified"]},{"year":2000,"claim":"Identified PTP1B as a direct STAT5B phosphatase that terminates signaling and blocks nuclear translocation, and flagged CrkL as a STAT5B-associated adapter.","evidence":"In vitro phosphatase assays and substrate-trapping PTP1B co-precipitation in mammary cells; co-IP of CrkL from TPO-stimulated platelets","pmids":["10993888","10720694"],"confidence":"High","gaps":["Other STAT5B phosphatases not excluded","CrkL association based on single-method co-IP at this stage"]},{"year":2002,"claim":"Distinguished the two nuclear-trafficking modes of STAT5B and extended its activation to EGFR/Src signaling, broadening the input space beyond classical cytokines.","evidence":"Leptomycin B, Tyr-699 and deletion mutants with fractionation in Ba/F3 cells; EGFR/Src tyrosine mutants with DNA-synthesis assays","pmids":["11971004","12429742"],"confidence":"High","gaps":["Import receptor for the dimer-dependent route not identified","Physiological relevance of monomer shuttling unresolved"]},{"year":2003,"claim":"Demonstrated isoform-selective STAT5B function in IFN-γ–induced IGF-I production and that a DNA-binding-domain mutation weakens target gene expression.","evidence":"Primary human fibroblasts with functional vs non-functional STAT5B and IGF-I mRNA readouts; NOD mouse L327M mutant with EMSA and target gene analysis","pmids":["14570891","14701862"],"confidence":"Medium","gaps":["STAT5A non-redundancy mechanism in IGF-I regulation not fully defined","L327M findings from a single genetic background"]},{"year":2006,"claim":"Established CrkL as a functional cofactor that enhances STAT5B DNA binding, rescuing a binding-defective mutant.","evidence":"Co-IP and recombinant CrkL profection with EMSA in NOD and congenic backgrounds","pmids":["16505237"],"confidence":"Medium","gaps":["Structural basis of CrkL-enhanced binding not defined","Single-lab finding"]},{"year":2012,"claim":"Identified Ser-193 as an mTOR-sensitive cytoplasmic phosphorylation site required for maximal STAT5B transcriptional activity, adding a serine-dependent layer to activation.","evidence":"Mass spectrometry, phospho-specific antibodies, mTOR/PP2A inhibitors, and site-directed mutagenesis in HEK293 reconstitution with EMSA/reporters","pmids":["22442148"],"confidence":"High","gaps":["Specific Ser-193 kinase not identified","How Ser-193 phosphorylation augments transcription mechanistically unclear"]},{"year":2017,"claim":"Connected STAT5B to circadian and Th17 regulatory inputs, placing CRY downstream of JAK2 in IGF-1 control and defining a RORγt→MSC→PP2A axis that dephosphorylates Ser-193.","evidence":"Cry-deficient mice with phospho-specific Western blotting; siRNA knockdown of MSC/PPP2R2B with PP2A and phospho-Ser-193 readouts in human Th17 cells","pmids":["28100634","28612433"],"confidence":"Medium","gaps":["Molecular link between CRY and Tyr-699 phosphorylation not defined","Each mechanism from a single lab"]},{"year":2018,"claim":"Defined the pathomechanism of dominant-negative STAT5B growth hormone insensitivity, showing mutants poison wild-type function by impairing nuclear localization or DNA binding while still dimerizing.","evidence":"Patient-derived cells with GH-stimulation, localization imaging, EMSA, and co-IP for heterodimerization","pmids":["29844444"],"confidence":"High","gaps":["Genotype-phenotype correlation for clinical severity not fully mapped","Quantitative dominant-negative threshold not established"]},{"year":2019,"claim":"Provided the structural and oncogenic mechanism of STAT5B activation, showing N642H increases pTyr-SH2 affinity, stabilizes the dimer, and confers dephosphorylation resistance, and that STAT5B drives leukemia by suppressing IFN responses.","evidence":"SPR, X-ray crystallography, MD simulations, and transgenic/syngeneic mouse models; STAT5A/B-specific knockouts with RNA-seq and IFN-inhibition rescue in BCR/ABL models","pmids":["25586472","31175292","30679796"],"confidence":"High","gaps":["Full set of leukemic target genes downstream of stabilized STAT5B not enumerated","How dephosphorylation resistance integrates with PTP1B in vivo unresolved"]},{"year":2022,"claim":"Defined a B-cell intrinsic brake function for STAT5B, showing it restrains IL-21-driven plasmablast differentiation via SOCS3 and BCL6.","evidence":"CRISPR STAT5B deletion in B-cell lines with phospho-flow and RNA-seq, plus STAT5B-null patient PBMC studies","pmids":["35469842"],"confidence":"High","gaps":["Direct STAT5B occupancy at SOCS3/BCL6 loci in primary B cells not detailed","Interplay with other STAT5B immune phenotypes not integrated"]},{"year":2024,"claim":"Established in vivo that C-terminal tyrosine phosphorylation of STAT5B is required for maximal IL-2-driven CD8+ T-cell proliferation through cell-cycle and receptor-expression programs.","evidence":"Tyr-to-Phe knockin mice with flow cytometry, RNA-seq, proteomics, and cell-cycle analysis","pmids":["39191751"],"confidence":"High","gaps":["Separation of STAT5A vs STAT5B contributions to the phenotype incomplete","Direct cell-cycle gene targets not individually validated"]},{"year":null,"claim":"The kinases responsible for Ser-193 phosphorylation and the labile feedback protein governing GH-signal termination remain molecularly unidentified, and the structural basis for paralog-specific target selection in vivo is unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Ser-193 kinase identity unknown","Feedback inhibitor protein not cloned","In vivo determinants of STAT5A/STAT5B target divergence beyond Gly-433 unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,26,31]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,4,21,31]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,3,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16,26]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,16,31]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[16,27]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,33,34,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[28,31,32,33]}],"complexes":[],"partners":["JAK2","PTP1B","CRKL","STAT5A","GR","EGFR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51692","full_name":"Signal transducer and activator of transcription 5B","aliases":[],"length_aa":787,"mass_kda":89.9,"function":"Carries out a dual function: signal transduction and activation of transcription (PubMed:29844444). Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription. Positively regulates hematopoietic/erythroid differentiation","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P51692/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT5B","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT5B","total_profiled":1310},"omim":[{"mim_id":"618985","title":"GROWTH HORMONE INSENSITIVITY SYNDROME WITH IMMUNE DYSREGULATION 2, AUTOSOMAL DOMINANT; GHISID2","url":"https://www.omim.org/entry/618985"},{"mim_id":"618796","title":"SAC3 DOMAIN-CONTAINING PROTEIN 1; SAC3D1","url":"https://www.omim.org/entry/618796"},{"mim_id":"612376","title":"ACUTE PROMYELOCYTIC LEUKEMIA; APL","url":"https://www.omim.org/entry/612376"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"608937","title":"SH2B ADAPTOR PROTEIN 1; SH2B1","url":"https://www.omim.org/entry/608937"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT5B"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P51692","domains":[{"cath_id":"1.10.532.10","chopping":"4-127","consensus_level":"high","plddt":88.4885,"start":4,"end":127},{"cath_id":"1.20.1050.20","chopping":"155-328","consensus_level":"high","plddt":94.1575,"start":155,"end":328},{"cath_id":"2.60.40.630","chopping":"338-472","consensus_level":"high","plddt":90.834,"start":338,"end":472},{"cath_id":"3.30.505.10","chopping":"503-683","consensus_level":"medium","plddt":93.6426,"start":503,"end":683}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51692","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51692-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51692-F1-predicted_aligned_error_v6.png","plddt_mean":85.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT5B","jax_strain_url":"https://www.jax.org/strain/search?query=STAT5B"},"sequence":{"accession":"P51692","fasta_url":"https://rest.uniprot.org/uniprotkb/P51692.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51692/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51692"}},"corpus_meta":[{"pmid":"9630227","id":"PMC_9630227","title":"Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9630227","citation_count":1020,"is_preprint":false},{"pmid":"7568026","id":"PMC_7568026","title":"Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7568026","citation_count":460,"is_preprint":false},{"pmid":"25586472","id":"PMC_25586472","title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25586472","citation_count":333,"is_preprint":false},{"pmid":"18347089","id":"PMC_18347089","title":"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18347089","citation_count":287,"is_preprint":false},{"pmid":"10851055","id":"PMC_10851055","title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851055","citation_count":281,"is_preprint":false},{"pmid":"9841920","id":"PMC_9841920","title":"Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9841920","citation_count":258,"is_preprint":false},{"pmid":"23596048","id":"PMC_23596048","title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23596048","citation_count":251,"is_preprint":false},{"pmid":"8961260","id":"PMC_8961260","title":"Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8961260","citation_count":214,"is_preprint":false},{"pmid":"10743504","id":"PMC_10743504","title":"Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation.","date":"1999","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10743504","citation_count":200,"is_preprint":false},{"pmid":"8631883","id":"PMC_8631883","title":"Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8631883","citation_count":183,"is_preprint":false},{"pmid":"10993888","id":"PMC_10993888","title":"A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10993888","citation_count":139,"is_preprint":false},{"pmid":"9528750","id":"PMC_9528750","title":"Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9528750","citation_count":131,"is_preprint":false},{"pmid":"12429742","id":"PMC_12429742","title":"STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12429742","citation_count":128,"is_preprint":false},{"pmid":"22912632","id":"PMC_22912632","title":"The STAT5b Pathway Defect and Autoimmunity.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22912632","citation_count":101,"is_preprint":false},{"pmid":"10630411","id":"PMC_10630411","title":"STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver.","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10630411","citation_count":100,"is_preprint":false},{"pmid":"10428824","id":"PMC_10428824","title":"Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428824","citation_count":98,"is_preprint":false},{"pmid":"28887441","id":"PMC_28887441","title":"HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28887441","citation_count":96,"is_preprint":false},{"pmid":"22361342","id":"PMC_22361342","title":"Mapping the growth hormone--Stat5b--IGF-I transcriptional circuit.","date":"2012","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/22361342","citation_count":91,"is_preprint":false},{"pmid":"21396575","id":"PMC_21396575","title":"STAT5b deficiency: lessons from STAT5b gene mutations.","date":"2011","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21396575","citation_count":90,"is_preprint":false},{"pmid":"29844444","id":"PMC_29844444","title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29844444","citation_count":86,"is_preprint":false},{"pmid":"10585399","id":"PMC_10585399","title":"STAT5b-deficient mice are growth hormone pulse-resistant. Role of STAT5b in sex-specific liver p450 expression.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10585399","citation_count":83,"is_preprint":false},{"pmid":"7559477","id":"PMC_7559477","title":"STAT3 and STAT5B are targets of two different signal pathways activated by hematopoietin receptors and control transcription via separate cytokine response elements.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7559477","citation_count":77,"is_preprint":false},{"pmid":"11929748","id":"PMC_11929748","title":"Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11929748","citation_count":76,"is_preprint":false},{"pmid":"17130555","id":"PMC_17130555","title":"Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17130555","citation_count":76,"is_preprint":false},{"pmid":"16787985","id":"PMC_16787985","title":"Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16787985","citation_count":75,"is_preprint":false},{"pmid":"10666213","id":"PMC_10666213","title":"Both stat5a and stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10666213","citation_count":74,"is_preprint":false},{"pmid":"30573779","id":"PMC_30573779","title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30573779","citation_count":71,"is_preprint":false},{"pmid":"10628751","id":"PMC_10628751","title":"Stat5b inhibits NFkappaB-mediated signaling.","date":"2000","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10628751","citation_count":70,"is_preprint":false},{"pmid":"26703237","id":"PMC_26703237","title":"STAT5B deficiency: Impacts on human growth and immunity.","date":"2015","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/26703237","citation_count":68,"is_preprint":false},{"pmid":"24440911","id":"PMC_24440911","title":"Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24440911","citation_count":68,"is_preprint":false},{"pmid":"24497979","id":"PMC_24497979","title":"Identification of STAT5A and STAT5B target genes in human T cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24497979","citation_count":68,"is_preprint":false},{"pmid":"23400594","id":"PMC_23400594","title":"Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23400594","citation_count":68,"is_preprint":false},{"pmid":"18793823","id":"PMC_18793823","title":"Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18793823","citation_count":68,"is_preprint":false},{"pmid":"10224108","id":"PMC_10224108","title":"Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224108","citation_count":67,"is_preprint":false},{"pmid":"9852045","id":"PMC_9852045","title":"A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9852045","citation_count":66,"is_preprint":false},{"pmid":"9231797","id":"PMC_9231797","title":"Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9231797","citation_count":65,"is_preprint":false},{"pmid":"31175292","id":"PMC_31175292","title":"Structural and functional consequences of the STAT5BN642H driver mutation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31175292","citation_count":64,"is_preprint":false},{"pmid":"9892011","id":"PMC_9892011","title":"Termination of growth hormone pulse-induced STAT5b signaling.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9892011","citation_count":64,"is_preprint":false},{"pmid":"11971004","id":"PMC_11971004","title":"Stat5B shuttles between cytoplasm and nucleus in a cytokine-dependent and -independent manner.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11971004","citation_count":60,"is_preprint":false},{"pmid":"24512550","id":"PMC_24512550","title":"Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.","date":"2014","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24512550","citation_count":57,"is_preprint":false},{"pmid":"10448095","id":"PMC_10448095","title":"PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10448095","citation_count":57,"is_preprint":false},{"pmid":"23071812","id":"PMC_23071812","title":"MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23071812","citation_count":56,"is_preprint":false},{"pmid":"9973252","id":"PMC_9973252","title":"Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9973252","citation_count":54,"is_preprint":false},{"pmid":"28100634","id":"PMC_28100634","title":"Cryptochromes regulate IGF-1 production and signaling through control of JAK2-dependent STAT5B phosphorylation.","date":"2017","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/28100634","citation_count":53,"is_preprint":false},{"pmid":"33255665","id":"PMC_33255665","title":"STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33255665","citation_count":49,"is_preprint":false},{"pmid":"12869640","id":"PMC_12869640","title":"Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12869640","citation_count":49,"is_preprint":false},{"pmid":"36755813","id":"PMC_36755813","title":"STAT5b: A master regulator of key biological pathways.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36755813","citation_count":48,"is_preprint":false},{"pmid":"11463580","id":"PMC_11463580","title":"Cross-talk between Stat5b and estrogen receptor-alpha and -beta in mammary epithelial cells.","date":"2001","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11463580","citation_count":48,"is_preprint":false},{"pmid":"30679796","id":"PMC_30679796","title":"Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30679796","citation_count":47,"is_preprint":false},{"pmid":"19966185","id":"PMC_19966185","title":"Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior.","date":"2009","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19966185","citation_count":47,"is_preprint":false},{"pmid":"14570891","id":"PMC_14570891","title":"Transcriptional regulation of insulin-like growth factor-I by interferon-gamma requires STAT-5b.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14570891","citation_count":46,"is_preprint":false},{"pmid":"23773921","id":"PMC_23773921","title":"Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells.","date":"2013","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/23773921","citation_count":45,"is_preprint":false},{"pmid":"26959237","id":"PMC_26959237","title":"Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26959237","citation_count":45,"is_preprint":false},{"pmid":"15364543","id":"PMC_15364543","title":"Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.","date":"2004","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15364543","citation_count":45,"is_preprint":false},{"pmid":"21205633","id":"PMC_21205633","title":"Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line.","date":"2010","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/21205633","citation_count":45,"is_preprint":false},{"pmid":"35210405","id":"PMC_35210405","title":"Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.","date":"2022","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/35210405","citation_count":44,"is_preprint":false},{"pmid":"26959975","id":"PMC_26959975","title":"Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26959975","citation_count":43,"is_preprint":false},{"pmid":"22729867","id":"PMC_22729867","title":"Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22729867","citation_count":38,"is_preprint":false},{"pmid":"23097626","id":"PMC_23097626","title":"STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23097626","citation_count":38,"is_preprint":false},{"pmid":"10720694","id":"PMC_10720694","title":"Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets.","date":"2000","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10720694","citation_count":38,"is_preprint":false},{"pmid":"24470975","id":"PMC_24470975","title":"JAK2-STAT5B pathway and osteoblast differentiation.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24470975","citation_count":37,"is_preprint":false},{"pmid":"22419735","id":"PMC_22419735","title":"A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22419735","citation_count":37,"is_preprint":false},{"pmid":"14701862","id":"PMC_14701862","title":"A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14701862","citation_count":37,"is_preprint":false},{"pmid":"17327369","id":"PMC_17327369","title":"Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding.","date":"2007","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17327369","citation_count":37,"is_preprint":false},{"pmid":"29377304","id":"PMC_29377304","title":"Regulation of human trophoblast cell syncytialization by transcription factors STAT5B and NR4A3.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29377304","citation_count":35,"is_preprint":false},{"pmid":"10984246","id":"PMC_10984246","title":"Pulsatility of growth hormone (GH) signalling in liver cells: role of the JAK-STAT5b pathway in GH action.","date":"2000","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/10984246","citation_count":35,"is_preprint":false},{"pmid":"16155412","id":"PMC_16155412","title":"Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells.","date":"2005","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16155412","citation_count":35,"is_preprint":false},{"pmid":"22442148","id":"PMC_22442148","title":"Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22442148","citation_count":33,"is_preprint":false},{"pmid":"29187589","id":"PMC_29187589","title":"STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29187589","citation_count":32,"is_preprint":false},{"pmid":"19630967","id":"PMC_19630967","title":"A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrin-mediated human breast cancer cell migration.","date":"2009","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/19630967","citation_count":32,"is_preprint":false},{"pmid":"22130676","id":"PMC_22130676","title":"Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22130676","citation_count":32,"is_preprint":false},{"pmid":"33122102","id":"PMC_33122102","title":"Human growth disorders associated with impaired GH action: Defects in STAT5B and JAK2.","date":"2020","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33122102","citation_count":31,"is_preprint":false},{"pmid":"31600547","id":"PMC_31600547","title":"Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function.","date":"2019","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31600547","citation_count":31,"is_preprint":false},{"pmid":"17509524","id":"PMC_17509524","title":"Hypoxia activates the IGF-1 expression through STAT5b in human HepG2 cells.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17509524","citation_count":29,"is_preprint":false},{"pmid":"35469842","id":"PMC_35469842","title":"STAT5B restrains human B-cell differentiation to maintain humoral immune homeostasis.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35469842","citation_count":27,"is_preprint":false},{"pmid":"24836440","id":"PMC_24836440","title":"BCR-ABL affects STAT5A and STAT5B differentially.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24836440","citation_count":27,"is_preprint":false},{"pmid":"29246863","id":"PMC_29246863","title":"Essential roles of stat5.1/stat5b in controlling fish somatic growth.","date":"2017","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/29246863","citation_count":27,"is_preprint":false},{"pmid":"26388045","id":"PMC_26388045","title":"Signal transducer and activator of transcription 5B (STAT5B) modulates adipocyte differentiation via MOF.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26388045","citation_count":27,"is_preprint":false},{"pmid":"16584384","id":"PMC_16584384","title":"Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16584384","citation_count":27,"is_preprint":false},{"pmid":"34716993","id":"PMC_34716993","title":"miR-146a enhances regulatory T-cell differentiation and function in allergic rhinitis by targeting STAT5b.","date":"2021","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/34716993","citation_count":26,"is_preprint":false},{"pmid":"11781356","id":"PMC_11781356","title":"Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11781356","citation_count":23,"is_preprint":false},{"pmid":"10835485","id":"PMC_10835485","title":"Molecular characterization of STAT5A- and STAT5B-encoding genes reveals extended intragenic sequence homogeneity in cattle and mouse and different degrees of divergent evolution of various domains.","date":"2000","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/10835485","citation_count":23,"is_preprint":false},{"pmid":"10729993","id":"PMC_10729993","title":"Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis.","date":"2000","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10729993","citation_count":22,"is_preprint":false},{"pmid":"27035235","id":"PMC_27035235","title":"Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27035235","citation_count":22,"is_preprint":false},{"pmid":"24335105","id":"PMC_24335105","title":"Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24335105","citation_count":22,"is_preprint":false},{"pmid":"17287404","id":"PMC_17287404","title":"Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation.","date":"2007","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17287404","citation_count":21,"is_preprint":false},{"pmid":"38802512","id":"PMC_38802512","title":"Perinatal thymic-derived CD8αβ-expressing γδ T cells are innate IFN-γ producers that expand in IL-7R-STAT5B-driven neoplasms.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38802512","citation_count":19,"is_preprint":false},{"pmid":"39792364","id":"PMC_39792364","title":"The histone lactylation of AIM2 influences the suppression of ferroptosis by ACSL4 through STAT5B and promotes the progression of lung cancer.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39792364","citation_count":19,"is_preprint":false},{"pmid":"28612433","id":"PMC_28612433","title":"Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling STAT5B activity.","date":"2017","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28612433","citation_count":19,"is_preprint":false},{"pmid":"22919439","id":"PMC_22919439","title":"Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells.","date":"2012","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/22919439","citation_count":19,"is_preprint":false},{"pmid":"39191751","id":"PMC_39191751","title":"Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39191751","citation_count":18,"is_preprint":false},{"pmid":"23906478","id":"PMC_23906478","title":"δ-opioid receptor activation leads to neurite outgrowth and neuronal differentiation via a STAT5B-Gαi/o pathway.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23906478","citation_count":18,"is_preprint":false},{"pmid":"16959781","id":"PMC_16959781","title":"Retracted: Glucocorticoids repress bcl-X expression in lymphoid cells by recruiting STAT5B to the P4 promoter.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16959781","citation_count":18,"is_preprint":false},{"pmid":"9528973","id":"PMC_9528973","title":"Lactogenic hormone-inducible phosphorylation and gamma-activated site-binding activities of Stat5b in primary rat Leydig cells and MA-10 mouse Leydig tumor cells.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9528973","citation_count":17,"is_preprint":false},{"pmid":"16531819","id":"PMC_16531819","title":"Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells.","date":"2006","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/16531819","citation_count":17,"is_preprint":false},{"pmid":"23053176","id":"PMC_23053176","title":"Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.","date":"2012","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/23053176","citation_count":17,"is_preprint":false},{"pmid":"20433855","id":"PMC_20433855","title":"Multi-component signaling complexes of the delta-opioid receptor with STAT5B and G proteins.","date":"2010","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20433855","citation_count":16,"is_preprint":false},{"pmid":"28219718","id":"PMC_28219718","title":"A novel regulatory role of RGS4 in STAT5B activation, neurite outgrowth and neuronal differentiation.","date":"2017","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28219718","citation_count":16,"is_preprint":false},{"pmid":"16505237","id":"PMC_16505237","title":"Impaired Crkl expression contributes to the defective DNA binding of Stat5b in nonobese diabetic mice.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16505237","citation_count":16,"is_preprint":false},{"pmid":"30621209","id":"PMC_30621209","title":"Epilepsy Associates with Decreased HIF-1α/STAT5b Signaling in Glioblastoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30621209","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52745,"output_tokens":9452,"usd":0.150007,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19880,"output_tokens":5081,"usd":0.113212,"stage2_stop_reason":"end_turn"},"total_usd":0.263219,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"STAT5B (then called Stat5b) was cloned from mouse mammary tissue and shown to recognize GAS sites (TTCNNNGAA) in vitro and mediate prolactin-induced transcription in COS cells co-transfected with the prolactin receptor, establishing its role as a transcriptional activator downstream of prolactin/JAK2 signaling.\",\n      \"method\": \"cDNA cloning, in vitro DNA-binding assays, COS cell transfection with PRL receptor and reporter genes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA-binding assays plus functional transcriptional reconstitution in COS cells; foundational cloning paper replicated by many subsequent studies\",\n      \"pmids\": [\"7568026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"STAT5B is activated by IL-2 in peripheral blood lymphocytes and NK-like cells. IL-2-induced STAT5B DNA-binding activity in COS-7 cells requires JAK3, the IL-2Rβ chain, the common γ-chain, and either Tyr-392 or Tyr-510 of IL-2Rβ as docking sites. Tyr-699 of STAT5B is required for dimerization.\",\n      \"method\": \"COS-7 reconstitution with specific antisera, dominant-negative constructs, site-directed tyrosine mutants of IL-2Rβ and STAT5B\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution system with mutagenesis of multiple tyrosine residues, replicated across multiple cell types\",\n      \"pmids\": [\"8631883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Upon prolactin-induced tyrosine phosphorylation, STAT5A and STAT5B form homo- and heterodimers and translocate to the nucleus, where both isoforms contribute to the DNA-binding activity detected during lactation. Stat5b homodimers are less abundant than Stat5a homodimers in mammary cells.\",\n      \"method\": \"Isoform-specific antibodies, EMSA, supershift analysis, immunodepletion, co-immunoprecipitation in mammary tissue/cells\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal biochemical methods (EMSA, IP, supershift) in physiologically relevant mammary tissue; replicated in subsequent studies\",\n      \"pmids\": [\"8961260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Growth hormone induces tyrosyl phosphorylation of both STAT5A and STAT5B, and JAK2 kinase is required for GH-dependent tyrosyl phosphorylation of STAT5B. The GH receptor's C-terminal cytoplasmic domain and Tyr-333/338 are required for maximal STAT5B activation.\",\n      \"method\": \"COS cell expression with GHR truncation/mutation constructs, JAK2-deficient cell lines (gamma2A-GHR vs. 2C4-GHR), Western blotting, EMSA\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — JAK2-deficient cell line rescue and GHR mutagenesis establishing mechanistic requirements; multiple orthogonal methods\",\n      \"pmids\": [\"9231797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT5A and STAT5B homodimers have distinct DNA-binding specificities determined by a single amino acid: Gly-433 in STAT5B (vs. Glu at the equivalent position in STAT5A) in the DNA-binding domain determines their differential DNA-binding preference.\",\n      \"method\": \"Chimeric STAT5 molecules, site-directed mutagenesis, EMSA with different GAS-site oligonucleotides\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with chimeric proteins plus point mutagenesis identifying single residue responsible for specificity difference\",\n      \"pmids\": [\"9852045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In mammary cells, STAT5A, STAT5B, and the glucocorticoid receptor (GR) are physically associated in vivo independently of lactogenic hormone treatment. Upon lactogenic hormone treatment, Stat5a-Stat5b heterodimers form and translocate to the nucleus. The GR does not bind the Stat5 DNA-binding site directly but is detectable in the Stat5-DNA complex, suggesting GR acts as a cofactor for milk protein gene transcription.\",\n      \"method\": \"Co-immunoprecipitation, immunodepletion, EMSA, HC11 mammary cell experiments at different developmental stages\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, immunodepletion, EMSA with supershift, multiple physiological contexts\",\n      \"pmids\": [\"9528750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT5B is essential for IL-2- and IL-15-mediated NK cell proliferation and cytolytic activity. Stat5b-/- mice show greatly diminished NK cell numbers and responsiveness, and diminished IL-2Rβ chain expression, establishing STAT5B as a non-redundant regulator of NK cell function via IL-2Rβ expression.\",\n      \"method\": \"Stat5b-knockout mice, anti-CD3 proliferation assays, NK cytolytic activity assays, flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype and molecular correlate (IL-2Rβ expression); replicated across IL-2 and IL-15 systems\",\n      \"pmids\": [\"9841920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Stat5a and Stat5b have essential and often redundant roles in cytokine responses. Stat5a is specifically required for prolactin-induced mammary gland development, while Stat5b is specifically required for growth hormone-mediated pubertal growth and sex-specific liver gene expression. Deletion of both leads to more severe phenotypes than single knockouts.\",\n      \"method\": \"Individual and double Stat5a/Stat5b gene-targeted knockout mice; phenotypic analysis of mammary, hepatic, and hematopoietic responses\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mice with defined tissue-specific phenotypes; multiple cytokine systems tested; widely replicated\",\n      \"pmids\": [\"9630227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"STAT5B is required for GH pulse-induced SOCS-2 and SOCS-3 expression in liver but not in mammary gland, demonstrating tissue-specific STAT5B-dependent regulation of negative feedback inhibitors of cytokine signaling.\",\n      \"method\": \"Comparison of GH-induced SOCS mRNA expression in wild-type vs. STAT5b-deficient mice by Northern/RT-PCR\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO comparison with tissue-specific resolution; single lab but clear genetic epistasis\",\n      \"pmids\": [\"10630411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"STAT5B is required for GH pulse responsiveness in liver. STAT5b-deficient mice fail to respond to pulsatile GH replacement with normal body weight gain, male-specific CYP2D9 expression, or suppression of female-specific CYP2B enzymes, establishing STAT5B as an essential mediator of pulsatile GH-driven sex-specific liver gene expression.\",\n      \"method\": \"Hypophysectomized wild-type vs. STAT5b-deficient mice with pulsatile GH replacement; liver P450 enzyme measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with pharmacological rescue (GH replacement) and multiple molecular readouts\",\n      \"pmids\": [\"10585399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Termination of GH pulse-induced STAT5B signaling involves: (1) synthesis of a labile protein factor (blocked by cycloheximide), (2) proteasome-dependent degradation (blocked by MG132), and (3) dephosphorylation by a phosphotyrosine phosphatase (blocked by pervanadate). A serine kinase (H7-sensitive) is required for down-regulation of JAK2 signaling to STAT5B.\",\n      \"method\": \"Rat liver cell line CWSV-1 with pharmacological inhibitors (cycloheximide, MG132, pervanadate, H7), kinetic Western blotting\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple mechanistic inhibitor experiments in a cell-based system, dissecting sequential pathway steps; single lab but multiple orthogonal inhibitors\",\n      \"pmids\": [\"9892011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Continuous (female-pattern) GH exposure down-regulates STAT5B activity in liver cells via enhanced dephosphorylation of both STAT5B and GHR-JAK2, with the latter step leading to increased internalization/degradation of the receptor-kinase complex. Pervanadate treatment reverses the down-regulation, confirming phosphotyrosine phosphatase involvement.\",\n      \"method\": \"CWSV-1 rat liver cell line, continuous vs. pulsatile GH treatment, pervanadate/proteasome inhibitors, EMSA for STAT5B DNA-binding activity\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mechanistic pharmacological dissection in liver cell model, multiple inhibitors, EMSA functional readouts; single lab\",\n      \"pmids\": [\"9973252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PRL-activated STAT5B selectively translocates to the nucleus upon src kinase activation, but src activation (unlike prolactin) does not activate a beta-casein reporter, suggesting src and JAK2 activate STAT5B via distinct mechanisms resulting in differential nuclear function. The C-terminal sequences of STAT5B mediate its selective nuclear translocation by src.\",\n      \"method\": \"Indirect immunofluorescence microscopy, dominant-negative JAK2 overexpression, co-transfection assays with beta-casein-luciferase reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular localization with functional consequence (reporter assay), dominant-negative approach; single lab, limited mechanistic follow-up of C-terminal domain requirement\",\n      \"pmids\": [\"10428824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PRL-activated STAT5B inhibits NF-κB-mediated transcription by competing for limiting coactivators (p300/CBP) in the nucleus. This inhibitory effect requires the C-terminus of STAT5B and STAT5B nuclear translocation, but is independent of STAT5B-DNA interactions.\",\n      \"method\": \"Co-transfection assays with NF-κB reporters, dominant-negative STAT5B, p300/CBP co-expression titration experiments\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter constructs and domain-deletion approach identify mechanism; single lab, COS cell system\",\n      \"pmids\": [\"10628751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5A and STAT5B in COS7 cells and in vitro. Overexpression of PTP1B inhibits nuclear translocation of both STAT5 isoforms and PRL-induced beta-casein gene transcription. Substrate-trapping PTP1B mutants co-precipitate tyrosine-phosphorylated STAT5.\",\n      \"method\": \"In vitro phosphatase assays, co-precipitation with substrate-trapping PTP1B mutants, retrovirus-mediated overexpression in mammary epithelial cells, reporter gene assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro assay plus substrate-trapping, functional consequences in physiologically relevant cell type; multiple orthogonal methods\",\n      \"pmids\": [\"10993888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In platelets stimulated with thrombopoietin (TPO), CrkL adapter protein is present in DNA-bound STAT5 complexes and binds predominantly to STAT5B, identifying CrkL as a STAT5B-associated protein in TPO signaling.\",\n      \"method\": \"EMSA, immunoprecipitation, Western blotting in TPO-stimulated human platelets\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-precipitation from physiologically stimulated primary cells; single method for CrkL-STAT5B association; single lab\",\n      \"pmids\": [\"10720694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT5B shuttles constitutively between nucleus and cytoplasm as a monomer (independent of cytokine stimulation), via a CRM1-dependent nuclear export mechanism. Cytokine-dependent nuclear import uses a different mechanism requiring Tyr-699 phosphorylation and dimerization, and the coiled-coil domain. The nuclear export is sensitive to leptomycin B.\",\n      \"method\": \"Leptomycin B treatment, Tyr-699 mutant STAT5B, deletion mutants, nuclear/cytoplasmic fractionation, immunofluorescence in Ba/F3 cells\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping with multiple mutants, pharmacological inhibitor, two distinct import/export mechanisms defined; single lab\",\n      \"pmids\": [\"11971004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT5B mediates EGF-induced DNA synthesis downstream of EGFR overexpression and c-Src co-overexpression. EGF-induced phosphorylation of STAT5B requires Tyr-845 of the EGFR (phosphorylated by c-Src). STAT5B phosphorylation involves Tyr-699 (required for transcriptional activation) and Tyr-725/740/743 in the C-terminus.\",\n      \"method\": \"Site-specific EGFR tyrosine mutants, dominant-negative STAT5B, kinase-defective c-Src, breast tumor cell lines and C3H10T1/2 fibroblasts, [3H]-thymidine incorporation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple site-directed mutants of both EGFR and STAT5B, dominant-negative approach, functional DNA synthesis readout; single lab\",\n      \"pmids\": [\"12429742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT5b-RARα fusion protein (APL) binds retinoic acid response elements (RAREs) as homodimer and as heterodimer with RXRα, inhibiting wild-type RARα/RXRα transactivation. The coiled-coil domain of STAT5b is required for homodimerization, inhibition of RARα/RXRα activity, and stability of the STAT5b-RARα/SMRT complex. STAT5b-RARα also enhances STAT3-dependent transcription via a distinct mechanism.\",\n      \"method\": \"RARE reporter assays, SMRT/TRAM-1 co-IP, domain deletion/mutation analysis in transfected cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter assays and co-IP with domain dissection; single lab, fusion protein context\",\n      \"pmids\": [\"11929748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ligand-activated PPARα and PPARγ inhibit GH-induced, STAT5B-dependent transcription by up to ~80% without blocking STAT5B tyrosine phosphorylation or DNA binding. The inhibition requires the AF-1 (N-terminal) domain of PPARα and occurs downstream of STAT5B activation, suggesting competition for nuclear cofactors. Conversely, GH-activated STAT5B also inhibits PPAR-regulated transcription, demonstrating bidirectional cross-inhibition.\",\n      \"method\": \"COS-1 cell co-transfection with PPAR and STAT5B reporters, PPAR domain mutants, constitutively active STAT5B, Western blotting for phosphorylation status\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple PPAR mutants and constitutively active STAT5B define mechanistic step; single lab, cell transfection system\",\n      \"pmids\": [\"12869640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IFN-γ preferentially activates STAT5B (not STAT5A) in primary human dermal fibroblasts, and this activation is required for IFN-γ-induced upregulation of IGF-I mRNA. In fibroblasts with non-functional STAT5B, only STAT5A is activated and IGF-I induction is severely blunted, demonstrating that STAT5A cannot substitute for STAT5B in IGF-I transcriptional regulation.\",\n      \"method\": \"Primary human fibroblasts with functional vs. non-functional STAT5B, IFN-γ stimulation, nuclear translocation assays, IGF-I mRNA quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — natural human cell genetic comparison plus nuclear localization tracking; single lab, primary cells\",\n      \"pmids\": [\"14570891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A NOD mouse mutation (L327M) in the DNA-binding domain of Stat5b results in weaker DNA binding, confirmed by DNA-protein binding assays and correlated with decreased mRNA and protein levels of Stat5b target genes IL-2Rβ and Pim1.\",\n      \"method\": \"Sequencing, homology modeling, DNA-protein binding assays (EMSA), Western blotting comparing NOD vs. B6 mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus binding assays plus in vivo target gene expression; single lab\",\n      \"pmids\": [\"14701862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HNF4α inhibits GH-activated STAT5B transcriptional activity by blocking GH-stimulated JAK2 tyrosine phosphorylation (upstream mechanism), while STAT5B synergistically enhances HNF4α-driven transcription of ApoCIII. This bidirectional cross-talk is selective (HNF4α does not affect IFN-γ/STAT1 activity).\",\n      \"method\": \"HepG2 cell co-transfection, dominant-negative PTP1B, pervanadate treatment, JAK2 and STAT5B phosphorylation Western blotting, promoter-reporter assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple promoter-reporter assays and phosphorylation analysis with pharmacological controls defining point of cross-talk; single lab\",\n      \"pmids\": [\"16584384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In T lymphocytes, glucocorticoids recruit STAT5B to the P4 promoter of bcl-X. STAT5B remains bound while GR is released; subsequent co-recruitment of SMRT and HDAC3 leads to histone H3 deacetylation, RNA Pol II departure, and transcriptional repression. Inhibition of STAT5 activity converts glucocorticoid repression to activation. [Note: paper is marked as retracted.]\",\n      \"method\": \"ChIP assays in S49 T cells and primary thymocytes, STAT5 inhibitor, STAT5B co-transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — paper is retracted; ChIP-based mechanistic finding cannot be relied upon\",\n      \"pmids\": [\"16959781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CrkL adapter protein co-precipitates with Stat5b and is a binding cofactor that enhances Stat5b DNA-binding ability. Recombinant CrkL profection significantly increases Stat5b DNA binding and rescues the binding defect of the NOD mutant Stat5b.\",\n      \"method\": \"Co-immunoprecipitation, recombinant protein profection, EMSA in NOD and congenic mouse backgrounds\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue with recombinant protein establishes CrkL as STAT5B binding cofactor; single lab\",\n      \"pmids\": [\"16505237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT5B associates constitutively with the C-terminal tail of the δ-opioid receptor (δ-OR). δ-OR stimulation leads to STAT5B tyrosine phosphorylation in a G protein (Gi/Go) and c-Src kinase-dependent manner. STAT5B, c-Src, and selective Gα and Gβγ subunits form a multi-component signaling complex (signalosome) at the δ-OR C-terminus.\",\n      \"method\": \"Co-immunoprecipitation in HEK293 cells stably expressing δ-OR, pertussis toxin (G protein inhibition), c-Src kinase assays, STAT5B transcriptional reporter assays\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, pharmacological G protein inhibition, and transcriptional assays; single lab\",\n      \"pmids\": [\"20433855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"STAT5B Ser-193 is a novel cytokine-induced (IL-2, IL-7, IL-9, IL-15) phosphorylation site that occurs in the cytoplasm prior to nuclear translocation. Ser-193 phosphorylation is sensitive to mTOR inhibitors (rapamycin) and enhanced by PP2A inhibition. Ser-193 phosphorylation is required for maximal STAT5B transcriptional activity (confirmed by site-directed mutagenesis). Constitutive Ser-193 phosphorylation is found in primary leukemia/lymphoma cells.\",\n      \"method\": \"Mass spectrometry identification, phospho-specific antibodies, mTOR/PP2A inhibitors, site-directed mutagenesis, HEK293 reconstitution assays, EMSA, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry identification of novel PTM site, site-directed mutagenesis confirming functional requirement, multiple orthogonal assays; single lab\",\n      \"pmids\": [\"22442148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ΔEGFR (EGFRvIII) activates STAT5B at Y699 in a Src family kinase-dependent manner (distinct from full-length EGF-stimulated EGFR). Phosphorylated STAT5B and ΔEGFR form a nuclear complex that binds DNA and occupies promoters (including Bcl-XL and Aurora A). STAT5B knockdown reduces Bcl-XL levels and sensitizes glioblastoma cells to cisplatin.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, siRNA knockdown, cisplatin cytotoxicity assays in glioblastoma cell lines and patient samples\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, ChIP, and functional knockdown studies; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22729867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Activating mutations of STAT5B (particularly N642H in the SH2 domain) are frequent in γδ-T and NK-cell lymphomas. The N642H mutation markedly increases the binding affinity of phosphotyrosine-Y699 for the SH2 domain (measured by surface plasmon resonance), prolonging phospho-STAT5B persistence and increasing binding to target sites.\",\n      \"method\": \"Next-generation and Sanger sequencing, surface plasmon resonance, molecular modelling, phospho-STAT5B Western blotting, JAK inhibitor growth assays in transduced cell lines and primary NK cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biophysical SPR measurement of binding affinity, molecular modelling, and functional cell assays; multiple lymphoma cohorts\",\n      \"pmids\": [\"25586472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cryptochromes (CRY1/2) control IGF-1 circadian rhythms by regulating JAK2-dependent phosphorylation of STAT5B at Y699 (JAK2-dependent site). Cry-deficient mice show markedly reduced Y699 STAT5B phosphorylation in liver and skeletal muscle despite normal JAK2 phosphorylation, placing CRY activity downstream of JAK2 in the IGF-1 pathway.\",\n      \"method\": \"Cry-deficient mouse model, phospho-specific STAT5B and JAK2 Western blotting in liver and skeletal muscle, IGF-1 ELISA, Igf-1 mRNA quantification\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with phospho-specific antibodies establishing pathway position downstream of JAK2; single lab\",\n      \"pmids\": [\"28100634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Musculin (MSC), expressed in human Th17 cells in a RORγt-dependent manner, upregulates PP2A regulatory subunit PPP2R2B, which dephosphorylates STAT5B Ser-193, reducing STAT5B DNA binding and transcriptional activity on IL-2 target genes in Th17 cells.\",\n      \"method\": \"siRNA knockdown of MSC and PPP2R2B, PP2A assays, STAT5B Ser-193 phospho-Western blotting, EMSA, reporter assays in primary human Th17 cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway from RORγt → MSC → PPP2R2B → PP2A → STAT5B Ser-193 dephosphorylation defined by knockdown and phospho-specific readouts; single lab\",\n      \"pmids\": [\"28612433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dominant-negative STAT5B missense mutations cause growth hormone insensitivity by two distinct mechanisms: either failure of nuclear localization or failure to bind canonical STAT5B DNA response elements. Despite being robustly tyrosine-phosphorylated, each mutant retains the ability to dimerize with wild-type STAT5B, disrupting wild-type transcriptional functions.\",\n      \"method\": \"Patient-derived cell studies, GH stimulation/phosphorylation assays, nuclear localization imaging, EMSA, co-IP for dimerization with wild-type STAT5B\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple patient mutations characterized with functional assays (phosphorylation, localization, DNA binding, dimerization), distinguishing mechanistic pathomechanisms; replicated across several mutations\",\n      \"pmids\": [\"29844444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of human STAT5B and STAT5B-N642H reveal that the N642H mutation leads to alternative SH2 domain conformations. Biophysical data indicate that STAT5B-N642H can adopt both hyper-activated and hyper-inactivated states with resistance to dephosphorylation. MD simulations show sustained interchain cross-domain interactions in N642H, conferring kinetic stability to the mutant anti-parallel dimer.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulations, biophysical dephosphorylation assays, transgenic mouse model, syngeneic transplant models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of wild-type and mutant protein combined with biophysical assays and in vivo mouse models; multiple orthogonal methods\",\n      \"pmids\": [\"31175292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT5B (but not STAT5A) is the major STAT5 isoform driving BCR/ABL+ leukemia. STAT5B-deficient BCR/ABL+ cells have markedly enhanced IFN-α and IFN-γ signaling signatures, and inhibition of IFN responses rescues BCR/ABL+ colony formation of Stat5b-deficient cells, demonstrating that STAT5B enables leukemic transformation by suppressing IFN-α/γ responses.\",\n      \"method\": \"STAT5A/B-specific knockouts in BCR/ABL cell models, RNA-seq profiling, IFN pathway inhibition rescue experiments, leukemia transplant models\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with RNA-seq and functional rescue by IFN inhibition; multiple experimental approaches and in vivo model\",\n      \"pmids\": [\"30679796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT5B restrains IL-21-induced human B-cell differentiation into plasmablasts by inducing SOCS3 (which attenuates IL-21 signaling) and BCL6 (which represses plasma cell formation and class switching). CRISPR-mediated STAT5B deletion in B-cell lines diminishes IL-21-mediated SOCS3 induction; STAT5B-null patients have expanded immunoglobulin class-switched B cells and follicular T helper cells.\",\n      \"method\": \"CRISPR-mediated STAT5B deletion in B-cell lines, phospho-flow cytometry, RNA-seq, patient PBMC studies, in vitro B-cell differentiation assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR deletion plus human patient validation, RNA-seq, and functional differentiation assays; multiple orthogonal methods\",\n      \"pmids\": [\"35469842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Tyrosine phosphorylation of both STAT5A and STAT5B (at the C-terminal tyrosine) is essential for maximal IL-2 signaling and CD8+ T-cell proliferation in vivo. Tyrosine-to-phenylalanine knockin mice show reduced CD8+ T cells, impaired IL-2-induced proliferation correlated with reduced Myc, pRB, cyclins, CDKs, and a partial G1→S block, as well as decreased IL-2Rβ and IL-2Rγ expression and reduced pERK and pAKT.\",\n      \"method\": \"Knockin mice with Tyr-to-Phe mutations in STAT5A and STAT5B, flow cytometry, transcriptomics (RNA-seq), proteomics, cell cycle analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockin mouse model with transcriptomic and proteomic analyses; multiple orthogonal methods establishing in vivo requirement for STAT5B tyrosine phosphorylation\",\n      \"pmids\": [\"39191751\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT5B is a latent cytoplasmic transcription factor that is activated by JAK2-mediated tyrosine phosphorylation (at Y699) downstream of multiple cytokine receptors (GHR, IL-2R, PRL-R, EpoR, and others), whereupon it dimerizes—forming homodimers with a DNA-binding preference determined by Gly-433—and translocates to the nucleus via two mechanisms (constitutive CRM1-dependent monomer shuttling and cytokine-induced dimer import); maximal transcriptional activity additionally requires Ser-193 phosphorylation by an mTOR-sensitive kinase; dephosphorylation by PTP1B terminates signaling; STAT5B regulates distinct target genes from STAT5A (single residue in the DNA-binding domain confers specificity), mediates GH-pulsatile sex-specific liver gene expression, IGF-1 production, NK cell maturation and cytolytic function, Treg homeostasis (via FOXP3 and IL-2Rα), B-cell differentiation restraint (via SOCS3/BCL6), and suppresses IFN-α/γ responses to facilitate leukemogenesis; gain-of-function mutations (especially N642H in the SH2 domain) increase pY-STAT5B persistence by enhancing phosphotyrosine–SH2 affinity and conferring dephosphorylation resistance, as revealed by crystal structures of wild-type and mutant STAT5B.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"STAT5B is a latent cytoplasmic transcription factor that converts cytokine and growth-factor receptor engagement into GAS-element–driven gene expression, functioning downstream of prolactin, IL-2, growth hormone, and other receptors [#0, #1, #3]. Receptor-associated JAK kinases phosphorylate STAT5B on Tyr-699, which is required for dimerization and is the obligate step for cytokine-induced nuclear import; in resting cells STAT5B shuttles constitutively as a monomer via a CRM1-dependent export route, whereas activated dimers use a distinct Tyr-699/coiled-coil–dependent import mechanism [#1, #16]. Maximal transcriptional output further requires a cytoplasmic, mTOR-sensitive Ser-193 phosphorylation that precedes nuclear translocation [#26]. STAT5B and the paralog STAT5A diverge functionally: a single DNA-binding-domain residue (Gly-433 in STAT5B versus Glu in STAT5A) sets differential GAS-site preference, and STAT5B is selectively required for growth-hormone–driven, sex-specific liver gene expression while STAT5A governs prolactin-induced mammary development [#4, #7, #9]. Through these activities STAT5B controls NK-cell proliferation and cytolytic function via IL-2Rβ, IFN-γ–induced IGF-1 production, and restraint of IL-21–driven B-cell differentiation through SOCS3 and BCL6 induction [#6, #20, #34]. Signaling is terminated by phosphotyrosine dephosphorylation, with PTP1B acting as a direct STAT5B phosphatase, together with serine-kinase- and proteasome-dependent feedback [#10, #14]. STAT5B drives leukemic transformation, in part by suppressing IFN-α/γ responses in BCR/ABL+ cells, and recurrent activating mutations—notably N642H in the SH2 domain—prolong phospho-STAT5B persistence by increasing phosphotyrosine–SH2 affinity and conferring dephosphorylation resistance, as defined by surface plasmon resonance and crystal structures of wild-type and mutant protein [#28, #32, #33]. Dominant-negative missense mutations in STAT5B cause growth hormone insensitivity by impairing either nuclear localization or DNA binding while still dimerizing with and poisoning wild-type protein [#31].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established STAT5B as a sequence-specific transcriptional activator acting downstream of cytokine receptor signaling, answering whether the cloned factor could directly drive hormone-induced transcription.\",\n      \"evidence\": \"cDNA cloning, in vitro GAS-site DNA-binding assays, and prolactin-receptor reporter reconstitution in COS cells\",\n      \"pmids\": [\"7568026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the upstream kinase or activation residues\", \"No endogenous target genes identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the receptor architecture and the obligate dimerization residue, showing STAT5B activation requires JAK3/IL-2Rβ docking tyrosines and STAT5B Tyr-699.\",\n      \"evidence\": \"COS-7 reconstitution with dominant-negative constructs and tyrosine point mutants of IL-2Rβ and STAT5B; EMSA in lymphocytes\",\n      \"pmids\": [\"8631883\", \"8961260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how the two paralogs differ functionally\", \"Mechanism of nuclear import not yet defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Placed STAT5B activation downstream of JAK2 at the growth hormone receptor, establishing the GHR cytoplasmic determinants required for phosphorylation.\",\n      \"evidence\": \"GHR truncation/mutation constructs and JAK2-deficient cell line rescue with Western blotting and EMSA\",\n      \"pmids\": [\"9231797\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate STAT5B from STAT5A physiological roles\", \"In vivo GH consequences untested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolved paralog specificity, showing a single DNA-binding-domain residue (Gly-433) governs differential GAS-site preference and that STAT5A and STAT5B have non-redundant tissue roles.\",\n      \"evidence\": \"Chimeric proteins and point mutagenesis with EMSA; individual and double Stat5a/Stat5b knockout mice\",\n      \"pmids\": [\"9852045\", \"9630227\", \"9841920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis for tissue-restricted requirement unresolved\", \"How a single residue rewires target selection in vivo not mapped\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined STAT5B as the essential mediator of pulsatile GH-driven, sex-specific liver gene expression and dissected the multi-step termination of GH signaling.\",\n      \"evidence\": \"Hypophysectomized STAT5b-deficient mice with pulsatile GH replacement and liver P450 readouts; rat liver cell models with cycloheximide, MG132, pervanadate, and H7 inhibitors\",\n      \"pmids\": [\"10585399\", \"10630411\", \"9892011\", \"9973252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the labile feedback protein not established\", \"Specific serine kinase and phosphatase not molecularly identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified PTP1B as a direct STAT5B phosphatase that terminates signaling and blocks nuclear translocation, and flagged CrkL as a STAT5B-associated adapter.\",\n      \"evidence\": \"In vitro phosphatase assays and substrate-trapping PTP1B co-precipitation in mammary cells; co-IP of CrkL from TPO-stimulated platelets\",\n      \"pmids\": [\"10993888\", \"10720694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other STAT5B phosphatases not excluded\", \"CrkL association based on single-method co-IP at this stage\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Distinguished the two nuclear-trafficking modes of STAT5B and extended its activation to EGFR/Src signaling, broadening the input space beyond classical cytokines.\",\n      \"evidence\": \"Leptomycin B, Tyr-699 and deletion mutants with fractionation in Ba/F3 cells; EGFR/Src tyrosine mutants with DNA-synthesis assays\",\n      \"pmids\": [\"11971004\", \"12429742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor for the dimer-dependent route not identified\", \"Physiological relevance of monomer shuttling unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated isoform-selective STAT5B function in IFN-γ–induced IGF-I production and that a DNA-binding-domain mutation weakens target gene expression.\",\n      \"evidence\": \"Primary human fibroblasts with functional vs non-functional STAT5B and IGF-I mRNA readouts; NOD mouse L327M mutant with EMSA and target gene analysis\",\n      \"pmids\": [\"14570891\", \"14701862\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"STAT5A non-redundancy mechanism in IGF-I regulation not fully defined\", \"L327M findings from a single genetic background\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established CrkL as a functional cofactor that enhances STAT5B DNA binding, rescuing a binding-defective mutant.\",\n      \"evidence\": \"Co-IP and recombinant CrkL profection with EMSA in NOD and congenic backgrounds\",\n      \"pmids\": [\"16505237\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of CrkL-enhanced binding not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified Ser-193 as an mTOR-sensitive cytoplasmic phosphorylation site required for maximal STAT5B transcriptional activity, adding a serine-dependent layer to activation.\",\n      \"evidence\": \"Mass spectrometry, phospho-specific antibodies, mTOR/PP2A inhibitors, and site-directed mutagenesis in HEK293 reconstitution with EMSA/reporters\",\n      \"pmids\": [\"22442148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Ser-193 kinase not identified\", \"How Ser-193 phosphorylation augments transcription mechanistically unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected STAT5B to circadian and Th17 regulatory inputs, placing CRY downstream of JAK2 in IGF-1 control and defining a ROR\\u03b3t\\u2192MSC\\u2192PP2A axis that dephosphorylates Ser-193.\",\n      \"evidence\": \"Cry-deficient mice with phospho-specific Western blotting; siRNA knockdown of MSC/PPP2R2B with PP2A and phospho-Ser-193 readouts in human Th17 cells\",\n      \"pmids\": [\"28100634\", \"28612433\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between CRY and Tyr-699 phosphorylation not defined\", \"Each mechanism from a single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the pathomechanism of dominant-negative STAT5B growth hormone insensitivity, showing mutants poison wild-type function by impairing nuclear localization or DNA binding while still dimerizing.\",\n      \"evidence\": \"Patient-derived cells with GH-stimulation, localization imaging, EMSA, and co-IP for heterodimerization\",\n      \"pmids\": [\"29844444\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation for clinical severity not fully mapped\", \"Quantitative dominant-negative threshold not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the structural and oncogenic mechanism of STAT5B activation, showing N642H increases pTyr-SH2 affinity, stabilizes the dimer, and confers dephosphorylation resistance, and that STAT5B drives leukemia by suppressing IFN responses.\",\n      \"evidence\": \"SPR, X-ray crystallography, MD simulations, and transgenic/syngeneic mouse models; STAT5A/B-specific knockouts with RNA-seq and IFN-inhibition rescue in BCR/ABL models\",\n      \"pmids\": [\"25586472\", \"31175292\", \"30679796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of leukemic target genes downstream of stabilized STAT5B not enumerated\", \"How dephosphorylation resistance integrates with PTP1B in vivo unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a B-cell intrinsic brake function for STAT5B, showing it restrains IL-21-driven plasmablast differentiation via SOCS3 and BCL6.\",\n      \"evidence\": \"CRISPR STAT5B deletion in B-cell lines with phospho-flow and RNA-seq, plus STAT5B-null patient PBMC studies\",\n      \"pmids\": [\"35469842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT5B occupancy at SOCS3/BCL6 loci in primary B cells not detailed\", \"Interplay with other STAT5B immune phenotypes not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established in vivo that C-terminal tyrosine phosphorylation of STAT5B is required for maximal IL-2-driven CD8+ T-cell proliferation through cell-cycle and receptor-expression programs.\",\n      \"evidence\": \"Tyr-to-Phe knockin mice with flow cytometry, RNA-seq, proteomics, and cell-cycle analysis\",\n      \"pmids\": [\"39191751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Separation of STAT5A vs STAT5B contributions to the phenotype incomplete\", \"Direct cell-cycle gene targets not individually validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The kinases responsible for Ser-193 phosphorylation and the labile feedback protein governing GH-signal termination remain molecularly unidentified, and the structural basis for paralog-specific target selection in vivo is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ser-193 kinase identity unknown\", \"Feedback inhibitor protein not cloned\", \"In vivo determinants of STAT5A/STAT5B target divergence beyond Gly-433 unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 26, 31]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 4, 21, 31]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 3, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16, 26]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 16, 31]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [16, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 33, 34, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [28, 31, 32, 33]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"JAK2\", \"PTP1B\", \"CrkL\", \"STAT5A\", \"GR\", \"EGFR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}